J. Infante

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors.

G. Curt, P. LoRusso, H. Burris, 2011 .

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

K. Flaherty, J. Sosman, Douglas B. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

J. Infante, H. Arkenau, M. Gordon, 2018, British journal of clinical pharmacology.

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

P. LoRusso, J. Infante, D. Ouellet, 2015, Journal of clinical pharmacology.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combined inhibition of BRAF and MEK in melanoma patients.

C. Swanton, J. Infante, 2014, The Lancet. Oncology.

Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.

Steven R. Abram, H. Burris, J. Infante, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

Giselle Limentani, P. LoRusso, Sunil Sharma, 2013, Journal of pharmaceutical sciences.

Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium

J. Hainsworth, J. Infante, R. Hauke, 2013, Melanoma research.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2013, Investigational New Drugs.

ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8

R. Hruban, A. Maitra, M. Goggins, 2008, The American journal of surgical pathology.

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

A. Tolcher, K. Papadopoulos, J. Bendell, 2016, Investigational New Drugs.

Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer

D. Porter, L. Zawel, H. Burris, 2010 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Plimack, M. Voss, P. Sharma, 2014 .

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Wei Xu, M. Herlyn, K. Nathanson, 2013, Cell reports.

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.

R. Sullivan, K. Flaherty, J. Sosman, 2017 .

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.

R. Sullivan, K. Flaherty, J. Sosman, 2015 .

Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.

M. Sznol, A. Shoushtari, J. Infante, 2019, Journal of Clinical Oncology.

Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

R. Sullivan, F. Hodi, P. Hwu, 2017 .

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty, Douglas B. Johnson, S. Patel, 2017 .

Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies

J. Tabernero, C. Rommel, P. Klein, 2012 .

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

J. Hainsworth, H. Burris, J. Infante, 2010, Cancer.

PARP inhibitors: pitfalls and promises.

H. Burris, J. Infante, 2013, The Lancet. Oncology.

A Phase I Dose-escalation and PK Study of continuous oral Rucaparib in Patients with advanced solid Tumors

Michael J. Flynn, Manish R. Patel, Geoffrey I. Shapiro, 2013 .

255PPhase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers

R. Korn, A. Tolcher, F. Meric-Bernstam, 2017 .

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

F. Hodi, J. Schellens, D. Kaufman, 2016 .

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

K. Morrissey, F. Hodi, P. LoRusso, 2017 .

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

S. de Vos, S. Ansell, J. Infante, 2014, Investigational New Drugs.

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

M. Sznol, B. Jakobsen, A. Shoushtari, 2016 .

A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.

Suzanne F. Jones, J. Hainsworth, J. Bendell, 2011, European journal of cancer.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

D. Camidge, S. Shreeve, H. Burris, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

J. Goldberg, J. Infante, J. Russell, 2022, Blood advances.

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

G. Curt, P. LoRusso, H. Burris, 2017, Investigational New Drugs.

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

J. Hainsworth, J. Bendell, J. Infante, 2013, Cancer biology & therapy.

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

J. Infante, A. Daud, Hongwei Wang, 2017 .

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.

J. Hainsworth, L. Hart, H. Burris, 2012, Lung cancer.

Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.

K. Flaherty, J. Sosman, I. Puzanov, 2012 .

Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

E. Mittra, A. DeMichele, F. Meric-Bernstam, 2015 .

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.

Suzanne F. Jones, H. Burris, J. Infante, 2014 .

Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2012, Clinical colorectal cancer.

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

R. Yeh, P. LoRusso, J. Infante, 2019, Investigational New Drugs.

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).

M. Voss, A. DeMichele, F. Meric-Bernstam, 2016 .

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

L. Chow, J. Infante, L. Siu, 2016 .

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2019, Journal of Immunotherapy for Cancer.

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

J. Bendell, J. Infante, R. Mayer, 2015, Cancer Chemotherapy and Pharmacology.

A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).

David S. Shames, David E. Gerber, Jeffrey R. Infante, 2013 .

ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors

G. Shapiro, P. LoRusso, J. Infante, 2016, Cancer Chemotherapy and Pharmacology.

A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent.

H. Burris, J. Infante, T. Reid, 2014 .

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.

Suzanne F. Jones, A. Tan, H. Burris, 2010, The oncologist.

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

Suzanne F. Jones, J. Hainsworth, J. Bendell, 2011, Cancer Chemotherapy and Pharmacology.

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

F. Peale, G. Shapiro, P. LoRusso, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. Goldstein, 2016 .

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.

B. Redman, B. Rini, H. Burris, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Suzanne F. Jones, M. Lacouture, M. Borad, 2011, Clinical Cancer Research.

Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

J. Schellens, J. Soria, Sunil Sharma, 2016 .

Tolerability of split-dose oprozomib (ONX 0912) in patients with advanced refractory or recurrent solid tumors.

A. Tolcher, K. Papadopoulos, H. Burris, 2012 .

PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors.

A. Bryce, T. Ames, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

J. Nemunaitis, G. Weiss, B. Sikic, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Investigational new drugs.

PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.

B. Costello, A. Bryce, T. Ames, 2020 .

CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients withmetastatic pancreatic cancer

M. Reni, J. Tabernero, D. Goldstein, 2016 .

A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).

J. Hamm, J. Infante, W. Edenfield, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors

J. Baselga, T. Wilson, D. Juric, 2013 .

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).

J. Infante, M. Millward, R. Kefford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.

A. Ravaud, L. Dirix, C. Britten, 2017 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.

G. Shapiro, F. Meric-Bernstam, J. Infante, 2017 .

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Yoon-Koo Kang, H. Safran, J. Infante, 2016 .

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.

F. Hodi, G. Gibney, N. Rizvi, 2013 .

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Suzanne F. Jones, D. V. Von Hoff, G. Weiss, 2014, European journal of cancer.

Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study

E. Plimack, M. Voss, P. Sharma, 2016 .

1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors

H. Wakelee, C. Liang, C. Lovly, 2014 .

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors.

M. Borad, P. LoRusso, H. Shepard, 2012 .

A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Cancer investigation.

A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

Suzanne F. Jones, A. Oza, M. O’Connor, 2016 .

Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL‐305) in patients with advanced solid tumors

Suzanne F. Jones, E. Chan, J. Bendell, 2009 .

Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.

A. Ravaud, L. Dirix, C. Britten, 2017 .

A phase I dose-escalation study of IMGN388 in patients with solid tumors.

A. Tolcher, A. Patnaik, J. Bendell, 2010 .

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, J. Infante, D. Rathkopf, 2019, Journal of Clinical Oncology.

1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.

David C. Smith, S. Tirrell, J. Infante, 2012 .

MLN9708, an investigational proteasome inhibitor, in patients (pts) with solid tumors: Updated phase I results.

David C. Smith, J. Infante, L. Siu, 2012 .

A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.

A. Tolcher, K. Papadopoulos, D. Rasco, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

E. Sausville, D. Siegel, S. Singhal, 2010 .

Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer

H. Kennecke, J. Infante, Bing‐Bing Yang, 2013, Clinical pharmacology in drug development.

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

J. Desai, Y. Bang, E. Kwak, 2016 .

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

A. Tolcher, F. Peale, K. Papadopoulos, 2013 .

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

Yulei N. Wang, L. Molinero, J. Infante, 2016 .

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.

Suzanne F. Jones, A. Tolcher, N. Le, 2011 .

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

R. Herbst, Y. Bang, J. Bono, 2014 .

Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.

Suzanne F. Jones, C. Liang, J. Bendell, 2012 .

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015 .

Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

J. Hecht, Z. Wainberg, K. Papadopoulos, 2018 .

Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

C. Atreya, R. Kurzrock, D. Ryan, 2014 .

Phase II study of NK012 in relapsed small cell lung cancer.

J. Hainsworth, J. Bendell, H. Burris, 2011, Journal of Clinical Oncology.

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

J. Hamm, J. Infante, W. Edenfield, 2013, Cancer.

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible

L. Dirix, M. Schlichting, J. Infante, 2016 .

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.

K. Flaherty, W. Miller, Carrie Lee, 2017 .

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).

K. Flaherty, J. Sosman, M. Sznol, 2013 .

Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.

J. Bendell, J. Infante, L. Fecher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer

F. Meric-Bernstam, T. Owonikoko, J. Harding, 2018 .

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

J. Bendell, J. Infante, W. Ma, 2015, Investigational New Drugs.

P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK

J. Neal, H. Wakelee, C. Liang, 2016 .

A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.

Suzanne F. Jones, J. Bendell, H. Burris, 2010 .

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2013 .

Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors

F. Peale, Yuan Chen, P. LoRusso, 2015 .

A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

J. Soria, H. Burris, J. Infante, 2010 .

PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.

F. Janku, J. Infante, A. Naing, 2017 .

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

A. Krishnan, J. Miguel, J. Goldberg, 2020 .

Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2013 .

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC)

J. Hainsworth, H. Burris, J. Infante, 2008 .

A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

Suzanne F. Jones, J. Barrett, Melissa L. Johnson, 2016 .

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Douglas B. Johnson, P. Ott, L. Hart, 2017 .

Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans

Suzanne F. Jones, A. Tjønneland, K. Overvad, 2017, British Journal of Cancer.

Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.

E. Sausville, K. Papadopoulos, A. Patnaik, 2010 .

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

Sunil Sharma, J. Infante, D. George, 2015, Cancer Chemotherapy and Pharmacology.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

G. Curt, P. LoRusso, H. Burris, 2017, BMC Cancer.

Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

J. Neal, H. Wakelee, C. Liang, 2016 .

A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.

Suzanne F. Jones, H. Burris, J. Infante, 2008, Clinical lung cancer.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

J. Infante, I. Braña, V. Moreno, 2020 .

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, International journal of nanomedicine.

Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.

K. Venkatakrishnan, S. Jalal, J. Infante, 2013 .

Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2015 .

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors.

R. Korn, M. Borad, P. LoRusso, 2013 .

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

C. Hoh, J. Bendell, H. Burris, 2014, British Journal of Cancer.

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence

J. Infante, H. Arkenau, C. Lemech, 2012, Therapeutic advances in medical oncology.

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

P. Ott, K. Papadopoulos, J. Infante, 2018, Cancer cell.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2013, European Journal of Clinical Pharmacology.

Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma

J. Infante, C. McNeil, O. Hamid, 2014 .

The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.

S. de Vos, E. Heath, J. Thompson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors.

N. Rizvi, P. Vicini, J. Infante, 2018, Annals of Oncology.

A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).

Yulei N. Wang, D. Gerber, J. Schiller, 2014 .

CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

J. Tabernero, D. Goldstein, J. Infante, 2013 .

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2021, Prostate Cancer and Prostatic Diseases.

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

A. Brenner, H. Burris, J. Infante, 2015 .

mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.

L. Hart, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.

K. Kelly, J. Infante, N. Iannotti, 2017 .

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

H. Burris, J. Infante, E. Dees, 2008 .